Journal of Tissue Science and Engineering

ISSN: 2157-7552

Open Access

Synergy between Rhbmp-2 and IKK-Inhibitor PS-1145 Delivered via a Porous Biodegradable Polymer Implant


David Carr, Nicole Y.C Yu, Jane Fitzpatrick, Lauren Peacock, Kathy Mikulec, Andrew J. Ruys, Justin C. Cooper-White, David G. Little and Aaron Schindeler

Critical-sized bone defects, whether caused by congenital malformation, tumor resection, trauma, or implant loosening, remain a major challenge for orthopaedic management. In this study we describe a bone tissue engineering approach in mice for the co-delivery of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the IKK inhibitor PS-1145.

Scaffold implants were manufactured from poly(lactide-co-glycolide)(PLGA) by Thermally-Induced Phase Separation (TIPS), with rhBMP-2 (10 μg) and the IKK inhibitor PS-1145 (0 μg, 40 μg or 80 μg) incorporated into the polymer. These scaffolds were then surgically implanted into the hind limb muscle of C57BL6/J mice. One group of mice also received systemic 50 mg/kg PS-1145 (days 11-20). Specimens were harvested at week 3 for X-ray and microCT analyses and descriptive histology.

Local and systemic delivery PS-1145 both significantly increased the net rhBMP-2 induced bone at 3 weeks. A maximal response was seen with the 40 μg PS-1145 group, although there was no significant difference between the 40 μg and 80 μg PS-1145 regimens. No local cytotoxicity was seen with either dose of PS-1145. In summary, local co-delivery of rhBMP-2 and PS-1145 via a porous PLGA scaffold represents a new tissue engineering approach for maintaining new bone in an unloaded environment.


Share this article

50+ Million Readerbase

Recommended Conferences

Journal Highlights

Google Scholar citation report
Citations: 715

Journal of Tissue Science and Engineering received 715 citations as per Google Scholar report

Journal of Tissue Science and Engineering peer review process verified at publons

Indexed In

Recommended Conferences
arrow_upward arrow_upward